Linked research, clinical, and regulatory source pathways.
Company profile
About MIM Software
MIM Software Inc., a GE HealthCare company, is a leading provider of vendor-neutral medical imaging software solutions that standardize clinical workflows and simplify increasingly complex healthcare scenarios. Founded over 20 years ago and headquartered in Cleveland, Ohio, MIM serves more than 3,300 global healthcare organizations across radiation oncology, radiology, nuclear medicine, and theranostics. The company's comprehensive software portfolio includes MIM Maestro for radiation therapy planning with AI-powered auto-contouring (Contour ProtégéAI+), MIM Encore for nuclear medicine workflow automation, MIM SurePlan for molecular radiotherapy dosimetry, and MIM Symphony for prostate imaging and brachytherapy planning. MIM's solutions integrate with major healthcare IT systems and are used by 90% of the world's top 50 hospitals. The company's technology enables clinicians to make more confident patient care decisions in less time through advanced image fusion, quantitative analysis, and workflow automation. MIM's vendor-neutral approach allows healthcare organizations to consolidate resources, boost efficiency, and deliver precision medicine at scale across their enterprise. Recent FDA clearances include MIM LesionID Pro for automated tumor burden analysis and Centiloid scaling tools for Alzheimer's disease imaging. As part of GE HealthCare, MIM continues to expand its capabilities in AI-driven imaging solutions and precision oncology care.
Company description MIM Software official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at MIM Software?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- Cancer (radiation oncology)
- Cardiac conditions
- Gynecologic cancers
- Liver cancer (Y90 therapy)
- Neurological conditions
- Prostate cancer
- PSMA-positive tumors
Who it serves
- Academic Medical Centers
- Cancer Centers
- Health Systems
- Imaging Centers
- Pharmaceutical Organizations
- Research Institutions
Deployment & integration
Deployment information is currently being developed.
Recorded integration context: EHR systems, Multiple imaging modalities (PET/CT, SPECT/CT, MRI, CT), PACS systems, Treatment Planning Systems (TPS).
Geographic context
MarketsGlobal · Organizations on every inhabited continent · USA
Company sourceOfficial website
Company milestones
Platform expansion
FDA 510(k) clearance for MIM LesionID Pro with automated pre-processing, FDA clearance for Centiloid scaling tool for Alzheimer's imaging, Launch of MIM ComboTherapy GYN HDR/EBRT, New reirradiation workflow in MIM Maestro, First combined software release with MIM Encore under GE HealthCare
Partnerships
Recorded partners
- GE HealthCare (parent company/acquirer)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · Jul 30, 2026
Enhancing PRRT Outcome Prediction in Neuroendocrine Tumors: Aggregated Multi-Lesion PET Radiomics Incorporating Inter-Tumor Heterogeneity.Cancers · Dec 4, 2025
Predicting radiation pneumonitis in lung cancer patients using robust 4DCT-ventilation and perfusion imaging.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · Nov 1, 2025
Assessing multiple MRI sequences in deep learning-based synthetic CT generation for MR-only radiation therapy of head and neck cancers.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · Apr 1, 2025
Automated daily dose accumulation workflow for treatment quality assurance during online adaptive radiotherapy with a 0.35T MR-linac.Journal of applied clinical medical physics · Mar 1, 2025
Development and validation of an AI-based lung lobe auto-contouring tool using radiation therapy planning free-breathing images.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · Jan 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Contour ProtégéAI+K253270 · 510k · Mar 27, 2026
Contour ProtégéAI+K250035 · 510k · Feb 3, 2025
Contour ProtégéAIK231765 · 510k · Nov 8, 2023
Contour ProtégéAIK223774 · 510k · Apr 6, 2023
Contour ProtégéAIK213976 · 510k · Feb 3, 2022
Contour ProtegeAIK210632 · 510k · Oct 20, 2021
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Reduced time to treatment
Radiation oncology workflow automation
Improved plan quality
AI auto-contouring and treatment planning
Reduced physician effort
Automated tumor burden analysis
Reduced turnaround times
Prostate imaging workflow
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from MIM Software
Recent articles published on MIM Software's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.